Robert Justice

14.4k total citations · 2 hit papers
61 papers, 6.4k citations indexed

About

Robert Justice is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Robert Justice has authored 61 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in Robert Justice's work include Cancer Treatment and Pharmacology (11 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Lung Cancer Treatments and Mutations (10 papers). Robert Justice is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Lung Cancer Treatments and Mutations (10 papers). Robert Justice collaborates with scholars based in United States, Malaysia and United Kingdom. Robert Justice's co-authors include Richard Pazdur, Martin H. Cohen, John R. Johnson, Rajeshwari Sridhara, Ann T. Farrell, Bhupinder Mann, Ramzi Dagher, Brian Booth, Shenghui Tang and Patricia Keegan and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Robert Justice

60 papers receiving 6.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma

2007 1.1k citations John R. Johnson, Martin H. Cohen et al. The Oncologist profile →
Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma

2007 407 citations Vicki Goodman, Edwin P. Rock et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Justice United States	40	2.8k	2.5k	1.7k	871	734	61	6.4k
M. E. Scheulen Germany	36	2.3k 0.8×	2.6k 1.0×	1.2k 0.7×	734 0.8×	597 0.8×	178	5.5k
Ferry A.L.M. Eskens Netherlands	43	2.6k 0.9×	2.9k 1.1×	1.5k 0.9×	1.2k 1.4×	283 0.4×	161	6.4k
Suzanne F. Jones United States	42	3.6k 1.3×	4.1k 1.6×	1.8k 1.0×	1.1k 1.3×	430 0.6×	231	7.8k
Alexander Laird United States	32	2.7k 1.0×	1.7k 0.7×	1.2k 0.7×	745 0.9×	664 0.9×	97	4.9k
Chris H. Takimoto United States	45	3.6k 1.3×	4.8k 1.9×	2.5k 1.5×	859 1.0×	758 1.0×	193	8.9k
S. Percy Ivy United States	43	4.1k 1.5×	3.6k 1.4×	1.3k 0.8×	1.3k 1.5×	376 0.5×	189	7.9k
Scott M. Wilhelm United States	28	3.5k 1.2×	2.8k 1.1×	1.6k 1.0×	1.3k 1.5×	334 0.5×	70	9.0k
Neeltje Steeghs Netherlands	37	1.7k 0.6×	2.8k 1.1×	1.9k 1.1×	857 1.0×	635 0.9×	242	5.4k
Carlo L. Bello United States	27	3.1k 1.1×	3.1k 1.2×	4.1k 2.4×	1.5k 1.7×	1.1k 1.4×	54	7.5k
Dick J. Richel Netherlands	43	3.5k 1.3×	4.5k 1.8×	1.7k 1.0×	2.2k 2.5×	769 1.0×	107	9.6k

Countries citing papers authored by Robert Justice

Since Specialization

Citations

This map shows the geographic impact of Robert Justice's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Justice with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Justice more than expected).

Fields of papers citing papers by Robert Justice

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Justice. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Justice. The network helps show where Robert Justice may publish in the future.

Co-authorship network of co-authors of Robert Justice

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Justice. A scholar is included among the top collaborators of Robert Justice based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Justice. Robert Justice is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Song, Pengfei, Sarah J. Schrieber, Qiang Xu, et al.. (2014). Exposure–Response Relationship of T-DM1: Insight Into Dose Optimization for Patients With HER2-Positive Metastatic Breast Cancer. Clinical Pharmacology & Therapeutics. 95(5). 558–564. 51 indexed citations

Amiri‐Kordestani, Laleh, Suparna Wedam, Lijun Zhang, et al.. (2014). First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer. Clinical Cancer Research. 20(21). 5359–5364. 114 indexed citations

Malik, Shakun, V. Ellen Maher, Karen E. Bijwaard, et al.. (2014). U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non–Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive. Clinical Cancer Research. 20(8). 2029–2034. 113 indexed citations

Pignatti, Francesco, Bertil Jönsson, Gideon M. Blumenthal, & Robert Justice. (2014). Assessment of benefits and risks in development of targeted therapies for cancer — The view of regulatory authorities. Molecular Oncology. 9(5). 1034–1041. 17 indexed citations

Miller, Barry W., Virginia E. Kwitkowski, Haleh Saber, et al.. (2014). U.S. Food and Drug Administration Approval: Obinutuzumab in Combination with Chlorambucil for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia. Clinical Cancer Research. 20(15). 3902–3907. 32 indexed citations

Kazandjian, Dickran, Gideon M. Blumenthal, Huanyu Chen, et al.. (2014). FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements. The Oncologist. 19(10). e5–e11. 225 indexed citations

Cohen, Martin H., John R. Johnson, Robert Justice, & Richard Pazdur. (2012). Approval Summary: Imatinib Mesylate for One or Three Years in the Adjuvant Treatment of Gastrointestinal Stromal Tumors. The Oncologist. 17(7). 992–997. 13 indexed citations

Zhang, Jenny J., Huanyu Chen, Kun He, et al.. (2012). Evaluation of Blinded Independent Central Review of Tumor Progression in Oncology Clinical Trials: A Meta-analysis. Therapeutic Innovation & Regulatory Science. 47(2). 167–174. 21 indexed citations

Theoret, Marc R., Yang‐Min Ning, Jenny J. Zhang, et al.. (2011). The Risks and Benefits of 5α-Reductase Inhibitors for Prostate-Cancer Prevention. New England Journal of Medicine. 365(2). 97–99. 98 indexed citations

10.

Brave, Michael H., Ann T. Farrell, Sarah Pope Miksinski, et al.. (2010). FDA Review Summary: Mozobil in Combination with Granulocyte Colony-Stimulating Factor to Mobilize Hematopoietic Stem Cells to the Peripheral Blood for Collection and Subsequent Autologous Transplantation. Oncology. 78(3-4). 282–288. 100 indexed citations

11.

Cohen, Martin H., Patricia Cortazar, Robert Justice, & Richard Pazdur. (2010). Approval Summary: Pemetrexed Maintenance Therapy of Advanced/Metastatic Nonsquamous, Non-Small Cell Lung Cancer (NSCLC). The Oncologist. 15(12). 1352–1358. 47 indexed citations

12.

Malik, Shakun, Ke Liu, Qiang Xu, et al.. (2010). Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary. Clinical Cancer Research. 16(20). 4921–4927. 38 indexed citations

13.

Sridhara, R., et al.. (2010). Review of Oncology and Hematology Drug Product Approvals at the US Food and Drug Administration Between July 2005 and December 2007. JNCI Journal of the National Cancer Institute. 102(4). 230–243. 76 indexed citations

14.

Ning, Y., et al.. (2010). FDA accelerated approval of anticancer agents.. Journal of Clinical Oncology. 28(15_suppl). 6065–6065.

15.

Rock, Edwin P., John K. Finkle, Howard Fingert, et al.. (2009). Assessing proarrhythmic potential of drugs when optimal studies are infeasible. American Heart Journal. 157(5). 827–836.e1. 64 indexed citations

16.

Cohen, Martin H., Robert Justice, & Richard Pazdur. (2009). Approval Summary: Pemetrexed in the Initial Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer. The Oncologist. 14(9). 930–935. 54 indexed citations

17.

Ryan, Qin, Amna Ibrahim, Martin H. Cohen, et al.. (2008). FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2. The Oncologist. 13(10). 1114–1119. 236 indexed citations

18.

Brave, Michael H., Vicki Goodman, Edvardas Kaminskas, et al.. (2008). Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate. Clinical Cancer Research. 14(2). 352–359. 190 indexed citations

19.

Brave, Michael H., Ramzi Dagher, Ann Farrell, et al.. (2006). Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer.. PubMed. 20(11). 1401–4, 1410; discussion 1410. 37 indexed citations

20.

Beitz, Julie, et al.. (1996). Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective.. PubMed. 7–9. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact